Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - simvastatin - filmom obložena tableta - 10 mg - urbroj: jedna filmom obložena tableta sadrži 10 mg simvastatina

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - simvastatin - filmom obložena tableta - 20 mg - urbroj: jedna filmom obložena tableta sadrži 20 mg simvastatina

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - simvastatin - filmom obložena tableta - 40 mg - urbroj: jedna filmom obložena tableta sadrži 40 mg simvastatina

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - simvastatin - caplets - simvastatin 80 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures.reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia). simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia).in patients at a high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease simvaxon is indicated to: - reduce the risk of total mortality by reducing chd deaths. - reduce the risk of non-fatal myocardial infarction and stroke. - reduce the need for coronary and non-coronary revascularization procedures

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - simvastatin - caplets - simvastatin 40 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measure

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - simvastatin - caplets - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia): simvaxon is indicated for the treatment of patients with hypertriglyceridemia (fredrickson type iv hyperlipidemia). dysbetalipoproteinemia (fredrickson type iii hyperlipidemia): simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia).

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - simvastatin - caplets - simvastatin 40 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia): simvaxon is indicated for the treatment of patients with hypertriglyceridemia (fredrickson type iv hyperlipidemia). dysbetalipoproteinemia (fredrickson type iii hyperlipidemia): simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia).

Israel - engelsk - Ministry of Health

dexcel pharma technologies ltd - simvastatin - caplets - simvastatin 20 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvaxon is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures - reduce the risk of stroke and transient ischemic attacks (tia's). hyperlipidemia: simvaxon is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvaxon therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia): simvaxon is indicated for the treatment of patients with hypertriglyceridemia (fredrickson type iv hyperlipidemia). dysbetalipoproteinemia (fredrickson type iii hyperlipidemia): simvaxon is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia).

Tunisia - fransk - Ministère de la Santé, Direction de l'inspection Pharmaceutique

ibn al baytar - simvastatine - comprimé pelliculé sécable - 20 mg - systeme cardiovasculaire - agents reduisant les lipides seriques - -hypercholestérolémies: -traitement des hypercholestérolémies primaires ou des dyslipidémies mixtes, en complément du régime,lorsque la réponse au régime et aux autres traitements non pharmacologiques(par exemple exercice physique, perte de poids) s'avère insuffisante. -traitement des hypercholestérolémies familiales homozygotes en complément du régime et des autres traitements hypolipémiants (par exemple aphérèse des ldl )ou si de tels traitements sont inappropriés. -prévention cardiovasculaire: -réduction de la mortalité et de la morbidité cardiovasculaires chez les patients ayant une pathologie cardiovasculaire avérée d'origine athéroscléreuse ou un diabète , avec cholestérol normal ou élevé en complément de l'effet de la correction des autres facteurs de risque et des autres traitements cardioprotecteurs.

Tunisia - fransk - Ministère de la Santé, Direction de l'inspection Pharmaceutique

ibn al baytar - simvastatine - comprimé pelliculé sécable - 40 mg - systeme cardiovasculaire - agents reduisant les lipides seriques - -hypercholestérolémies: -traitement des hypercholestérolémies primaires ou des dyslipidémies mixtes, en complément du régime,lorsque la réponse au régime et aux autres traitements non pharmacologiques(par exemple exercice physique, perte de poids) s'avère insuffisante. -traitement des hypercholestérolémies familiales homozygotes en complément du régime et des autres traitements hypolipémiants (par exemple aphérèse des ldl )ou si de tels traitements sont inappropriés. -prévention cardiovasculaire: -réduction de la mortalité et de la morbidité cardiovasculaires chez les patients ayant une pathologie cardiovasculaire avérée d'origine athéroscléreuse ou un diabète , avec cholestérol normal ou élevé en complément de l'effet de la correction des autres facteurs de risque et des autres traitements cardioprotecteurs.